CLEANClean Science And Technology Ltd.
Clean Science And Technology Q2 FY27 Results: Consolidated Net Profit ₹55.73 Crore on Total Income of ₹305 Crore
- Earnings
- Specialty chemicals
Reviewed byRachit TripathiBlacklitt Research
Clean Science And Technology (NSE: CLEAN) reported consolidated total income of ₹305.05 crore and net profit of ₹55.73 crore for the quarter ended 30 Sep 2026, it said in a filing on 31 Oct 2026. Standalone total income was ₹236.95 crore and standalone net profit ₹55.35 crore.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹305.05 crore, up 21.4% YoY and 5.0% QoQ
- Net profit and EPS: ₹55.73 crore, up 0.5% YoY and down 24.0% QoQ; basic EPS ₹5.24
- Finance costs: ₹1.94 crore against ₹0.07 crore a year earlier
- GST provision: Interest and non-creditable tax provision of ₹2.02 crore in the quarter
Standalone
The company on its own, without its subsidiaries
- Total income: ₹236.95 crore, up 8.5% YoY and 3.7% QoQ
- Net profit and EPS: ₹55.35 crore, down 14.4% YoY and 24.5% QoQ; basic EPS ₹5.21
- Finance costs: ₹1.48 crore against ₹0.05 crore a year earlier
- GST provision: Interest and non-creditable tax provision of ₹1.59 crore in the quarter
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 305.05 | 251.27 | +21.4% | 290.65 | +5.0% | |
| Revenue from operations | 299.39 | 244.60 | +22.4% | 268.43 | +11.5% |
| Other income | 5.66 | 6.67 | -15.1% | 22.22 | -74.5% |
| 55.73 | 55.43 | +0.5% | 73.35 | -24.0% | |
| Profit before tax | 74.42 | 74.86 | -0.6% | 97.55 | -23.7% |
| Finance costs | 1.94 | 0.07 | n/a | 0.05 | n/a |
| Depreciation | 21.38 | 18.83 | +13.5% | 21.05 | +1.6% |
| Tax expense | 18.69 | 19.43 | -3.8% | 24.20 | -22.8% |
| Net profit margin | 18.27% | 22.06% | -3.79 pp | 25.24% | -6.97 pp |
| EPS, basic (₹) | 5.24 | 5.22 | +0.4% | 6.90 | -24.1% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Consolidated total income rose 21.4% YoY, with revenue from operations up 22.4% to ₹299.39 crore, while other income fell 15.1% to ₹5.66 crore. Net profit grew only 0.5%, so profit grew more slowly than income. Profit before tax fell 0.6%, and the tax expense dropped 3.8% to ₹18.69 crore.
Other income is a small part of the total: ₹5.66 crore is 1.9% of total income and 7.6% of profit before tax this quarter. In the June quarter other income was ₹22.22 crore, so the sequential fall of 74.5% in that line is large against a small base for the current quarter.
Finance costs rose to ₹1.94 crore from ₹0.07 crore a year earlier, which is 0.6% of total income. The filing does not give the reason for the rise. Depreciation increased 13.5% YoY to ₹21.38 crore.
The filing says Clean Fino-Chem Limited, a wholly owned subsidiary, entered an agreement on 16 Jul 2026 with Geneus Chem AG, Switzerland, for exclusive manufacturing and supply of advanced grades of HALS products. In lieu of collaboration, Geneus Chem AG agreed to issue warrants exercisable within four years, under which the subsidiary would acquire 25% of Geneus Chem AG's share capital on a fully diluted basis. The company says the subsidiary has completed product trials for these grades after the half year ended 30 Sep 2026.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 236.95 | 218.41 | +8.5% | 228.49 | +3.7% | |
| Revenue from operations | 232.93 | 211.31 | +10.2% | 207.10 | +12.5% |
| Other income | 4.02 | 7.09 | -43.3% | 21.39 | -81.2% |
| 55.35 | 64.64 | -14.4% | 73.29 | -24.5% | |
| Profit before tax | 73.91 | 85.93 | -14.0% | 97.52 | -24.2% |
| Finance costs | 1.48 | 0.05 | n/a | 0.03 | n/a |
| Depreciation | 10.77 | 11.16 | -3.5% | 10.71 | +0.6% |
| Tax expense | 18.56 | 21.29 | -12.8% | 24.23 | -23.4% |
| Net profit margin | 23.36% | 29.59% | -6.23 pp | 32.08% | -8.72 pp |
| EPS, basic (₹) | 5.21 | 6.08 | -14.3% | 6.90 | -24.5% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone total income rose 8.5% YoY to ₹236.95 crore, with revenue from operations up 10.2%, but other income fell 43.3% to ₹4.02 crore. Net profit fell 14.4% to ₹55.35 crore, more than the 14.0% fall in profit before tax, and tax expense fell 12.8%.
Standalone other income of ₹4.02 crore is 5.4% of profit before tax of ₹73.91 crore. Standalone finance costs were ₹1.48 crore, against ₹0.05 crore a year earlier.
The consolidated net profit of ₹55.73 crore is ₹0.38 crore higher than the standalone figure, and the year-on-year trends differ: consolidated net profit rose 0.5% while standalone net profit fell 14.4%.
The filing reports a GST matter. During the quarter the Maharashtra GST Department conducted search and inspection proceedings under Section 67 of the Maharashtra GST Act, 2017, concluded on 29 Sep 2026. The Department has indicated a GST liability under reverse charge of ₹73.70 million standalone and ₹99.85 million consolidated, with interest and non-creditable tax liabilities. The company says discussions with GST authorities are ongoing, the amounts are not yet finally concluded, and it has deposited amounts corresponding to the RCM liability and interest in its GST electronic cash ledger.
Inference
The filing says the company's ESOP 2021 scheme led to the allotment of 6,822 equity shares of ₹1 each during the half year ended 30 Sep 2026. The board approved the results on 31 Oct 2026, and the statutory auditors issued a limited review report with an unmodified conclusion on both sets of results.
The filing does not state the final GST amount or how the GST matter will be concluded, and it does not give the expected financial impact of the Geneus Chem AG arrangement on future results. The reason for the rise in consolidated finance costs is also not stated.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
